Xingbo Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xingbo Xu has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Gerd Hasenfuß
Universitätsmedizin Göttingen, Herzzentrum, Klinik für Kardiologie und Pneumologie, Georg-August-Universität, Göttingen, Deutschland
4 shared publications Xiaoying Tan
Department of Nephrology and Rheumatology, University Medical Center Göttingen , Robert-Koch-Str. 40, Göttingen 37075
4 shared publications- Baolong Cui
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Robert-Koch-Str. 42a, 37075 Göttingen, Germany
3 shared publications - Baoqiang Song
Department of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, China
3 shared publications - Karl Toischer
Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; German Center for Cardiovascular Research, Partner Site Lower Saxony, Göttingen, Germany
3 shared publications - Xiaoying Tan
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Robert-Koch-Str. 42a, 37075 Göttingen, Germany
3 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Elsevier in Military Medical Research
- Vol. 13 (1)
From RCT to mechanistic study: ATRA reverses myofibroblast activation by reprogramming glucose metabolism via HIC1 and PCK1/2 to attenuate hypertrophic scar formation
- 27 April 2026
- Published by Elsevier in Military Medical Research
- Vol. 13 (1)
Open AccessFrom RCT to mechanistic study: ATRA reverses myofibroblast activation by reprogramming glucose metabolism via HIC1 and PCK1/2 to attenuate hypertrophic scar formation
- 2 April 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 122 (7) , 919-934
Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis
Cardiac fibrosis remains a significant and currently untreatable contributor to mortality in chronic heart disease. This study aimed to comprehensively map cell-specific pathological changes in fibrotic heart tissue from aortic stenosis patients using single-nucleus RNA sequencing (snRNA-seq). We specifically sought to identify novel cell-specific candidate genes involved in cardiac fibrosis and validate their functional impact using both in vitro and in vivo models. Our ultimate goal was to enhance the understanding of fibrogenesis in aortic stenosis, thereby guiding the development of targeted antifibrotic therapies. We conducted single nucleus RNA sequencing (snRNA-seq) on human fibrotic aortic stenosis and non-failing donor heart samples. The final dataset consisted of 41 330 nuclei distributed across 28 cell clusters representing 6 major cell types. SnRNA-seq revealed a disease-specific subpopulation of fibroblasts, characterized by the presence of both anti-fibrotic and pro-fibrotic markers. Interestingly, TCF21, a basic helix-loop-helix transcription factor, was identified as a potential key regulator within this distinct fibroblast population, and we performed functional studies to identify its role in disease progression accordingly. Loss of TCF21 in cardiac fibroblasts caused increased myofibroblast-like gene expression and differentiation, whereas upregulation of TCF21 in cardiac fibroblasts exerted an anti-fibrotic effect. Adeno-associated virus–mediated cardiac fibroblast-specific knockdown and overexpression in vivo further demonstrate that TCF21 improves cardiac remodelling. This investigation highlights the role of TCF21 as a protective regulator in cardiac fibrosis. Moreover, the upregulation of TCF21 holds promise as a strategy for treating cardiac fibrosis.
- 2 April 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 122 (7) , 919-934
Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis
Cardiac fibrosis remains a significant and currently untreatable contributor to mortality in chronic heart disease. This study aimed to comprehensively map cell-specific pathological changes in fibrotic heart tissue from aortic stenosis patients using single-nucleus RNA sequencing (snRNA-seq). We specifically sought to identify novel cell-specific candidate genes involved in cardiac fibrosis and validate their functional impact using both in vitro and in vivo models. Our ultimate goal was to enhance the understanding of fibrogenesis in aortic stenosis, thereby guiding the development of targeted antifibrotic therapies. We conducted single nucleus RNA sequencing (snRNA-seq) on human fibrotic aortic stenosis and non-failing donor heart samples. The final dataset consisted of 41 330 nuclei distributed across 28 cell clusters representing 6 major cell types. SnRNA-seq revealed a disease-specific subpopulation of fibroblasts, characterized by the presence of both anti-fibrotic and pro-fibrotic markers. Interestingly, TCF21, a basic helix-loop-helix transcription factor, was identified as a potential key regulator within this distinct fibroblast population, and we performed functional studies to identify its role in disease progression accordingly. Loss of TCF21 in cardiac fibroblasts caused increased myofibroblast-like gene expression and differentiation, whereas upregulation of TCF21 in cardiac fibroblasts exerted an anti-fibrotic effect. Adeno-associated virus–mediated cardiac fibroblast-specific knockdown and overexpression in vivo further demonstrate that TCF21 improves cardiac remodelling. This investigation highlights the role of TCF21 as a protective regulator in cardiac fibrosis. Moreover, the upregulation of TCF21 holds promise as a strategy for treating cardiac fibrosis.
- Open Access
CRISPR/Cas13-Based Anti-RNA Viral Approaches
RNA viruses pose significant threats to global health, causing diseases such as COVID-19, HIV/AIDS, influenza, and dengue. These viruses are characterized by high mutation rates, rapid evolution, and the ability to evade traditional antiviral therapies, making effective treatment and prevention particularly challenging. In recent years, CRISPR/Cas13 has emerged as a promising antiviral tool due to its ability to specifically target and degrade viral RNA. Unlike conventional antiviral strategies, Cas13 functions at the RNA level, providing a broad-spectrum and programmable approach to combating RNA viruses. Its flexibility allows for rapid adaptation of guide RNAs to counteract emerging viral variants, making it particularly suitable for highly diverse viruses such as SARS-CoV-2 and HIV. This review discusses up-to-date applications of Cas13 in targeting a wide range of RNA viruses, including SARS-CoV-2, HIV, dengue, influenza, and other RNA viruses, focusing on its therapeutic potential. Preclinical studies have demonstrated Cas13’s efficacy in degrading viral RNA and inhibiting replication, with applications spanning prophylactic interventions to post-infection treatments. However, challenges such as collateral cleavage, inefficient delivery, potential immunogenicity, and the development of an appropriate ethical framework must be addressed before clinical translation. Future research should focus on optimizing crRNA design, improving delivery systems, and conducting rigorous preclinical evaluations to enhance specificity, safety, and therapeutic efficacy. With continued advancements, Cas13 holds great promise as a revolutionary antiviral strategy, offering novel solutions to combat some of the world’s most persistent viral threats.
Open AccessCRISPR/Cas13-Based Anti-RNA Viral Approaches
RNA viruses pose significant threats to global health, causing diseases such as COVID-19, HIV/AIDS, influenza, and dengue. These viruses are characterized by high mutation rates, rapid evolution, and the ability to evade traditional antiviral therapies, making effective treatment and prevention particularly challenging. In recent years, CRISPR/Cas13 has emerged as a promising antiviral tool due to its ability to specifically target and degrade viral RNA. Unlike conventional antiviral strategies, Cas13 functions at the RNA level, providing a broad-spectrum and programmable approach to combating RNA viruses. Its flexibility allows for rapid adaptation of guide RNAs to counteract emerging viral variants, making it particularly suitable for highly diverse viruses such as SARS-CoV-2 and HIV. This review discusses up-to-date applications of Cas13 in targeting a wide range of RNA viruses, including SARS-CoV-2, HIV, dengue, influenza, and other RNA viruses, focusing on its therapeutic potential. Preclinical studies have demonstrated Cas13’s efficacy in degrading viral RNA and inhibiting replication, with applications spanning prophylactic interventions to post-infection treatments. However, challenges such as collateral cleavage, inefficient delivery, potential immunogenicity, and the development of an appropriate ethical framework must be addressed before clinical translation. Future research should focus on optimizing crRNA design, improving delivery systems, and conducting rigorous preclinical evaluations to enhance specificity, safety, and therapeutic efficacy. With continued advancements, Cas13 holds great promise as a revolutionary antiviral strategy, offering novel solutions to combat some of the world’s most persistent viral threats.
- Open Access
- 20 June 2025
- Published by MDPI AG in Preprints.org
CRISPR/Cas13-Based Anti-RNA Viral Approaches
RNA viruses pose significant threats to global health, causing diseases such as COVID-19, HIV/AIDS, influenza, and dengue. These viruses are characterized by high mutation rates, rapid evolution, and the ability to evade traditional antiviral therapies, making effective treatment and prevention particularly challenging. In recent years, CRISPR/Cas13 has emerged as a promising antiviral tool due to its ability to specifically target and degrade viral RNA. Unlike conventional antiviral strategies, Cas13 functions at the RNA level, providing a broad-spectrum and programmable approach to combating RNA viruses. Its flexibility allows for rapid adaptation of guide RNAs to counteract emerging viral variants, making it particularly suitable for highly diverse viruses such as SARS-CoV-2 and HIV. This review discusses up-to-date applications of CRISPR/Cas13 in targeting a wide range of RNA viruses, including SARS-CoV-2, HIV, Dengue, Influenza and other RNA viruses, with the main focus on its potential in therapeutic context. Preclinical studies have demonstrated Cas13’s efficacy in degrading viral RNA and inhibiting replication, with applications spanning prophylactic interventions to post-infection treatments. However, challenges such as collateral cleavage, inefficient delivery, potential immunogenicity as well as development of a concurrent ethical basis must be addressed before clinical translation. Future research should focus on optimizing crRNA design, improving delivery systems, and conducting rigorous preclinical evaluations to enhance specificity, safety, and therapeutic efficacy. With continued advancements, CRISPR/Cas13 holds great promise as a revolutionary antiviral strategy, offering new solutions to combat some of the world’s most persistent viral threats.
- 20 June 2025
- Published by MDPI AG in Preprints.org
Open AccessCRISPR/Cas13-Based Anti-RNA Viral Approaches
RNA viruses pose significant threats to global health, causing diseases such as COVID-19, HIV/AIDS, influenza, and dengue. These viruses are characterized by high mutation rates, rapid evolution, and the ability to evade traditional antiviral therapies, making effective treatment and prevention particularly challenging. In recent years, CRISPR/Cas13 has emerged as a promising antiviral tool due to its ability to specifically target and degrade viral RNA. Unlike conventional antiviral strategies, Cas13 functions at the RNA level, providing a broad-spectrum and programmable approach to combating RNA viruses. Its flexibility allows for rapid adaptation of guide RNAs to counteract emerging viral variants, making it particularly suitable for highly diverse viruses such as SARS-CoV-2 and HIV. This review discusses up-to-date applications of CRISPR/Cas13 in targeting a wide range of RNA viruses, including SARS-CoV-2, HIV, Dengue, Influenza and other RNA viruses, with the main focus on its potential in therapeutic context. Preclinical studies have demonstrated Cas13’s efficacy in degrading viral RNA and inhibiting replication, with applications spanning prophylactic interventions to post-infection treatments. However, challenges such as collateral cleavage, inefficient delivery, potential immunogenicity as well as development of a concurrent ethical basis must be addressed before clinical translation. Future research should focus on optimizing crRNA design, improving delivery systems, and conducting rigorous preclinical evaluations to enhance specificity, safety, and therapeutic efficacy. With continued advancements, CRISPR/Cas13 holds great promise as a revolutionary antiviral strategy, offering new solutions to combat some of the world’s most persistent viral threats.
- Open Access
- 9 May 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-22
CILP1 interacting with YBX1 promotes hypertrophic scar formation by suppressing PPARs transcription
Hypertrophic scar (HS) represents the most prevalent form of skin fibrosis, significantly impacting the quality of life. Despite this, the molecular mechanisms driving HS formation remain largely undefined, impeding the development of effective treatments. The study showed that Cartilage Intermediate Layer Protein 1 (CILP1) was predominantly expressed in myofibroblasts and was up-regulated in various forms of skin fibrosis, including human hypertrophic and keloid scars, and in animal models of HS. Notably, we detected elevated serum levels of CILP1 in fifty-two patients with HS compared to twenty healthy individuals, suggesting its potential as a novel biomarker. The findings indicated that CILP1 was involved in a negative feedback loop with TGF-β and inhibited the transcription of Peroxisome Proliferator-Activated Receptors (PPARs) via interaction with Y-box-binding protein 1 (YBX1). This interaction promoted cell proliferation, migration, and collagen production in hypertrophic scar fibroblasts (HSFs). In vivo studies further confirmed that CILP1 knockdown markedly reduced HS formation, whereas administration of recombinant human CILP1 protein exacerbated it. These discoveries illuminated the CILP1-YBX1-PPARs signaling pathway as a key regulator of HS formation, offering a foundation for novel therapeutic approaches.
- 9 May 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-22
Open AccessCILP1 interacting with YBX1 promotes hypertrophic scar formation by suppressing PPARs transcription
Hypertrophic scar (HS) represents the most prevalent form of skin fibrosis, significantly impacting the quality of life. Despite this, the molecular mechanisms driving HS formation remain largely undefined, impeding the development of effective treatments. The study showed that Cartilage Intermediate Layer Protein 1 (CILP1) was predominantly expressed in myofibroblasts and was up-regulated in various forms of skin fibrosis, including human hypertrophic and keloid scars, and in animal models of HS. Notably, we detected elevated serum levels of CILP1 in fifty-two patients with HS compared to twenty healthy individuals, suggesting its potential as a novel biomarker. The findings indicated that CILP1 was involved in a negative feedback loop with TGF-β and inhibited the transcription of Peroxisome Proliferator-Activated Receptors (PPARs) via interaction with Y-box-binding protein 1 (YBX1). This interaction promoted cell proliferation, migration, and collagen production in hypertrophic scar fibroblasts (HSFs). In vivo studies further confirmed that CILP1 knockdown markedly reduced HS formation, whereas administration of recombinant human CILP1 protein exacerbated it. These discoveries illuminated the CILP1-YBX1-PPARs signaling pathway as a key regulator of HS formation, offering a foundation for novel therapeutic approaches.
- Open Access
- 28 March 2025
- Published by Elsevier in Redox Biology
- Vol. 82, 103619
Targeting PIM1 by Bruceine D attenuates skin fibrosis via myofibroblast ferroptosis
- 28 March 2025
- Published by Elsevier in Redox Biology
- Vol. 82, 103619
Open AccessTargeting PIM1 by Bruceine D attenuates skin fibrosis via myofibroblast ferroptosis
- 29 June 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (13) , 1505-1507
Single-nucleus transcriptomics reveals adrenergic and STAT3 signalling in paradoxical low-flow low-gradient-specific cardiomyocyte subclusters: implications for aortic stenosis pathogenesis and treatment
Xingbo Xu, Xiaoying Tan, Baolong Cui, Niels B Paul, Manar Elkenani, Bo E Beuthner, Weichao Li, Belal A Mohamed, Moritz Schnelle, Miriam Puls, Elisabeth M Z
- 29 June 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (13) , 1505-1507
Single-nucleus transcriptomics reveals adrenergic and STAT3 signalling in paradoxical low-flow low-gradient-specific cardiomyocyte subclusters: implications for aortic stenosis pathogenesis and treatment
Xingbo Xu, Xiaoying Tan, Baolong Cui, Niels B Paul, Manar Elkenani, Bo E Beuthner, Weichao Li, Belal A Mohamed, Moritz Schnelle, Miriam Puls, Elisabeth M Z
- Open Access
- 20 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5885
DNA Methylation Analysis Identifies Novel Epigenetic Loci in Dilated Murine Heart upon Exposure to Volume Overload
Left ventricular (LV) dilatation, a prominent risk factor for heart failure (HF), precedes functional deterioration and is used to stratify patients at risk for arrhythmias and cardiac mortality. Aberrant DNA methylation contributes to maladaptive cardiac remodeling and HF progression following pressure overload and ischemic cardiac insults. However, no study has examined cardiac DNA methylation upon exposure to volume overload (VO) despite being relatively common among HF patients. We carried out global methylome analysis of LV harvested at a decompensated HF stage following exposure to VO induced by aortocaval shunt. VO resulted in pathological cardiac remodeling, characterized by massive LV dilatation and contractile dysfunction at 16 weeks after shunt. Although methylated DNA was not markedly altered globally, 25 differentially methylated promoter regions (DMRs) were identified in shunt vs. sham hearts (20 hypermethylated and 5 hypomethylated regions). The validated hypermethylated loci in Junctophilin-2 (Jph2), Signal peptidase complex subunit 3 (Spcs3), Vesicle-associated membrane protein-associated protein B (Vapb), and Inositol polyphosphate multikinase (Ipmk) were associated with the respective downregulated expression and were consistently observed in dilated LV early after shunt at 1 week after shunt, before functional deterioration starts to manifest. These hypermethylated loci were also detected peripherally in the blood of the shunt mice. Altogether, we have identified conserved DMRs that could be novel epigenetic biomarkers in dilated LV upon VO exposure.
- 20 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5885
Open AccessDNA Methylation Analysis Identifies Novel Epigenetic Loci in Dilated Murine Heart upon Exposure to Volume Overload
Left ventricular (LV) dilatation, a prominent risk factor for heart failure (HF), precedes functional deterioration and is used to stratify patients at risk for arrhythmias and cardiac mortality. Aberrant DNA methylation contributes to maladaptive cardiac remodeling and HF progression following pressure overload and ischemic cardiac insults. However, no study has examined cardiac DNA methylation upon exposure to volume overload (VO) despite being relatively common among HF patients. We carried out global methylome analysis of LV harvested at a decompensated HF stage following exposure to VO induced by aortocaval shunt. VO resulted in pathological cardiac remodeling, characterized by massive LV dilatation and contractile dysfunction at 16 weeks after shunt. Although methylated DNA was not markedly altered globally, 25 differentially methylated promoter regions (DMRs) were identified in shunt vs. sham hearts (20 hypermethylated and 5 hypomethylated regions). The validated hypermethylated loci in Junctophilin-2 (Jph2), Signal peptidase complex subunit 3 (Spcs3), Vesicle-associated membrane protein-associated protein B (Vapb), and Inositol polyphosphate multikinase (Ipmk) were associated with the respective downregulated expression and were consistently observed in dilated LV early after shunt at 1 week after shunt, before functional deterioration starts to manifest. These hypermethylated loci were also detected peripherally in the blood of the shunt mice. Altogether, we have identified conserved DMRs that could be novel epigenetic biomarkers in dilated LV upon VO exposure.
- Open Access
- 22 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (16)
Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer
Metastatic pancreatic cancer (PDAC) has a poor clinical outcome with a 5-year survival rate below 3%. Recent transcriptome profiling of PDAC biopsies has identified 2 clinically distinct subtypes — the “basal-like” (BL) subtype with poor prognosis and therapy resistance compared with the less aggressive and drug-susceptible “classical” (CLA) subtype. However, the mechanistic events and environmental factors that promote the BL subtype identity are not very clear. Using preclinical models, patient-derived xenografts, and FACS-sorted PDAC patient biopsies, we report here that the axon guidance receptor, roundabout guidance receptor 3 (ROBO3), promotes the BL metastatic program via a potentially unique AXL/IL-6/phosphorylated STAT3 (p-STAT3) regulatory axis. RNA-Seq identified a ROBO3-mediated BL-specific gene program, while tyrosine kinase profiling revealed AXL as the key mediator of the p-STAT3 activation. CRISPR/dCas9-based ROBO3 silencing disrupted the AXL/p-STAT3 signaling axis, thereby halting metastasis and enhancing therapy sensitivity. Transcriptome analysis of resected patient tumors revealed that AXL hi neoplastic cells associated with the inflammatory stromal program. Combining AXL inhibitor and chemotherapy substantially restored a CLA phenotypic state and reduced disease aggressiveness. Thus, we conclude that a ROBO3-driven hierarchical network determines the inflammatory and prometastatic programs in a specific PDAC subtype.
- 22 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (16)
Open AccessAxon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer
Metastatic pancreatic cancer (PDAC) has a poor clinical outcome with a 5-year survival rate below 3%. Recent transcriptome profiling of PDAC biopsies has identified 2 clinically distinct subtypes — the “basal-like” (BL) subtype with poor prognosis and therapy resistance compared with the less aggressive and drug-susceptible “classical” (CLA) subtype. However, the mechanistic events and environmental factors that promote the BL subtype identity are not very clear. Using preclinical models, patient-derived xenografts, and FACS-sorted PDAC patient biopsies, we report here that the axon guidance receptor, roundabout guidance receptor 3 (ROBO3), promotes the BL metastatic program via a potentially unique AXL/IL-6/phosphorylated STAT3 (p-STAT3) regulatory axis. RNA-Seq identified a ROBO3-mediated BL-specific gene program, while tyrosine kinase profiling revealed AXL as the key mediator of the p-STAT3 activation. CRISPR/dCas9-based ROBO3 silencing disrupted the AXL/p-STAT3 signaling axis, thereby halting metastasis and enhancing therapy sensitivity. Transcriptome analysis of resected patient tumors revealed that AXL hi neoplastic cells associated with the inflammatory stromal program. Combining AXL inhibitor and chemotherapy substantially restored a CLA phenotypic state and reduced disease aggressiveness. Thus, we conclude that a ROBO3-driven hierarchical network determines the inflammatory and prometastatic programs in a specific PDAC subtype.
- RetractedOpen Access
- 17 August 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 6776050
[Retracted] Marine‐Derived Piericidin Diglycoside S18 Alleviates Inflammatory Responses in the Aortic Valve via Interaction with Interleukin 37
Calcific aortic valve disease (CAVD) is a valvular disease frequently in the elderly individuals that can lead to the valve dysfunction. Osteoblastic differentiation of human aortic valve interstitial cells (HAVICs) induced by inflammation play a crucial role in CAVD pathophysiological processes. To date, no effective drugs for CAVD have been established, and new agents are urgently needed. Piericidin glycosides, obtained from a marine‐derived Streptomyces strain, were revealed to have regulatory effects on mitochondria in previous studies. Here, we discovered that 13‐hydroxypiericidin A 10‐O‐α‐D‐glucose (1→6)‐β‐D‐glucoside (S18), a specific piericidin diglycoside, suppresses lipopolysaccharide‐ (LPS) induced inflammatory responses of HAVICs by alleviating mitochondrial stress in an interleukin (IL)‐37‐dependent manner. Knockdown of IL‐37 by siRNA not only exaggerated LPS‐induced HAVIC inflammation and mitochondrial stress but also abrogated the anti‐inflammatory effect of S18 on HAVICs. Moreover, S18 alleviated aortic valve lesions in IL‐37 transgenic mice of CAVD model. Microscale thermophoresis (MST) and docking analysis of five piericidin analogues suggested that diglycosides, but not monoglycosides, exert obvious IL‐37‐binding activity. These results indicate that S18 directly binds to IL‐37 to alleviate inflammatory responses in HAVICs and aortic valve lesions in mice. Piericidin diglycoside S18 is a potential therapeutic agent to prevent the development of CAVD.
- 17 August 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 6776050
RetractedOpen Access[Retracted] Marine‐Derived Piericidin Diglycoside S18 Alleviates Inflammatory Responses in the Aortic Valve via Interaction with Interleukin 37
Calcific aortic valve disease (CAVD) is a valvular disease frequently in the elderly individuals that can lead to the valve dysfunction. Osteoblastic differentiation of human aortic valve interstitial cells (HAVICs) induced by inflammation play a crucial role in CAVD pathophysiological processes. To date, no effective drugs for CAVD have been established, and new agents are urgently needed. Piericidin glycosides, obtained from a marine‐derived Streptomyces strain, were revealed to have regulatory effects on mitochondria in previous studies. Here, we discovered that 13‐hydroxypiericidin A 10‐O‐α‐D‐glucose (1→6)‐β‐D‐glucoside (S18), a specific piericidin diglycoside, suppresses lipopolysaccharide‐ (LPS) induced inflammatory responses of HAVICs by alleviating mitochondrial stress in an interleukin (IL)‐37‐dependent manner. Knockdown of IL‐37 by siRNA not only exaggerated LPS‐induced HAVIC inflammation and mitochondrial stress but also abrogated the anti‐inflammatory effect of S18 on HAVICs. Moreover, S18 alleviated aortic valve lesions in IL‐37 transgenic mice of CAVD model. Microscale thermophoresis (MST) and docking analysis of five piericidin analogues suggested that diglycosides, but not monoglycosides, exert obvious IL‐37‐binding activity. These results indicate that S18 directly binds to IL‐37 to alleviate inflammatory responses in HAVICs and aortic valve lesions in mice. Piericidin diglycoside S18 is a potential therapeutic agent to prevent the development of CAVD.